Company intelligence / Profile preview

Insulinova

United States

Ownership: Private
Development stage: Other

Overview

Insulinova is a newly formed joint venture (2025) between Avant Technologies and SGAustria aiming to commercialize a proprietary stem cell differentiation plus encapsulation approach to provide a sustained, safe, and scalable diabetes cell therapy. No clinical results in humans have been released; the company’s near-term goal is initiating a Phase 1 trial in the United States[2][3][6].

Therapeutic areas: Endocrinology
Modalities: Cell therapyEncapsulated stem cell therapyBiologic
Industry: Biotech

Partnerships

Avant TechnologiesSGAustria (related to Austrianova)

Beyond the preview

Go deeper on Insulinova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulinova.

Explore the full profile